Bisharah Rizvi
Bisharah Rizvi has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Akhil Jain
The University of Texas MD Anderson Cancer Center 1 Department of Leukemia Houston, Texas
2 shared publications - Rupak Desai
Atlanta VA Medical Center, Decatur, GA
2 shared publications - Zainab Gandhi
Internal Medicine, Geisinger Wyoming Valley Medical Center, WIlkes Barre, PA, United States
2 shared publications - Agatha Olawunmi Akinsete
Department of Medicine and Surgery, Obafemi Awolowo University, Ile-Ife, Osun State, Nigeria
1 shared publication - Aleen Rahman
Department of Internal Medicine, Fatima Jinnah Med University, Lahore, Pakistan
1 shared publication - Ankit Vyas
Department of Vascular Medicine, Ochsner Clinic Foundation, New Orleans, LA, USA
1 shared publication
Latest Publications
- Open Access
- 1 June 2025
- Published by AME Publishing Company in Mediastinum
- Vol. 9, 12
Complications of linear endobronchial ultrasound guided biopsies: narrative review
Background and Objective: Linear endobronchial ultrasound (EBUS) has become a key tool for diagnosing pulmonary diseases, offering high diagnostic yield for both malignant and non-malignant conditions. With its increased use, more complications are being reported. The objective of this narrative review is to discuss the complications associated with linear EBUS. Methods: A literature search using PubMed and Google Scholar from 2009 to 2024 was done. We included case reports, prospective, and retrospective studies reporting linear EBUS complications. Key Content and Findings: Overall complications from EBUS range from 0.04% to 17%. Most common are infectious complications which are 0.04–4%. These include mediastinitis, pneumonia, pericarditis, bacteremia, tumor bed infection, lung abscess, empyema, and septic shock. Other complications include pneumothorax, pneumomediastinum, pneumopericardium, pneumoperitoneum, and subcutaneous emphysema. Complications due to anesthesia or equipment malfunction can occur as well. Hemorrhagic complications have been reported as well. Mortality is low 0.01–0.04%, and four cases have been reported that led to death from complications. Conclusions: With increased use of EBUS as a diagnostic tool, number of complications will increase. Clinicians performing the procedures should be aware of types of possible complications that can occur and follow the patients closely after the procedure. Rapid diagnosis and treatment should be done to avoid fatal outcomes.
- 1 June 2025
- Published by AME Publishing Company in Mediastinum
- Vol. 9, 12
Open AccessComplications of linear endobronchial ultrasound guided biopsies: narrative review
Background and Objective: Linear endobronchial ultrasound (EBUS) has become a key tool for diagnosing pulmonary diseases, offering high diagnostic yield for both malignant and non-malignant conditions. With its increased use, more complications are being reported. The objective of this narrative review is to discuss the complications associated with linear EBUS. Methods: A literature search using PubMed and Google Scholar from 2009 to 2024 was done. We included case reports, prospective, and retrospective studies reporting linear EBUS complications. Key Content and Findings: Overall complications from EBUS range from 0.04% to 17%. Most common are infectious complications which are 0.04–4%. These include mediastinitis, pneumonia, pericarditis, bacteremia, tumor bed infection, lung abscess, empyema, and septic shock. Other complications include pneumothorax, pneumomediastinum, pneumopericardium, pneumoperitoneum, and subcutaneous emphysema. Complications due to anesthesia or equipment malfunction can occur as well. Hemorrhagic complications have been reported as well. Mortality is low 0.01–0.04%, and four cases have been reported that led to death from complications. Conclusions: With increased use of EBUS as a diagnostic tool, number of complications will increase. Clinicians performing the procedures should be aware of types of possible complications that can occur and follow the patients closely after the procedure. Rapid diagnosis and treatment should be done to avoid fatal outcomes.
- Open Access
- 28 January 2025
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 26 (2) , 43-47
Depression Paradox in Cardiovascular Outcomes of Adult Patients with Obstructive Sleep Apnea: Insights from 2 Million Nationwide Hospitalizations
Depression Paradox in Cardiovascular Outcomes of Adult Patients with Obstructive Sleep Apnea: Insights from 2 Million Nationwide Hospitalizations - Thoracic Research and Practice
- 28 January 2025
- Published by Galenos Yayinevi in Thoracic Research and Practice
- Vol. 26 (2) , 43-47
Open AccessDepression Paradox in Cardiovascular Outcomes of Adult Patients with Obstructive Sleep Apnea: Insights from 2 Million Nationwide Hospitalizations
Depression Paradox in Cardiovascular Outcomes of Adult Patients with Obstructive Sleep Apnea: Insights from 2 Million Nationwide Hospitalizations - Thoracic Research and Practice
- Open Access
- 28 November 2023
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 22, 1200-1210
Prevalence and impact of tobacco use disorder on in-hospital mortality in patients hospitalized with non-group 1 pulmonary hypertension
Numerous studies indicated that patients with tobacco use disorder (TUD) are inversely associated with mortality in what is known as the smoker's paradox. However, limited studies have been conducted on the impact of TUD on the in-hospital mortality rates of patients with secondary pulmonary hypertension (PH, Non-Group 1 PH). Using the 2019 National Inpatient Sample, we identified PH and divided it into TUD and non-TUD to compare the comorbidities and in-hospital mortality between the two after 1:1 propensity-score matching. Of 1,129,440 PH hospitalizations, 12.1 % had TUD. After matching (n=133545, each group), TUD had lower median age (62 vs. 63), higher females (49 vs. 46.6 %), blacks (25.9 vs. 25.3 %), lower household income (40.8 vs. 32.7 %), Medicaid (22.4 vs. 14.8 %), non-elective (93.5 vs. 89.8 %), rural (9.3 vs. 6.7 %), urban non-teaching (17.2 vs 15.8 %) admissions. All CV comorbidities and other substance use were higher in TUD except CHF and valvular heart disease, TUD+ cohort and lower mortality (3.3 vs. 4.2 %, OR 0.78, p<0.001), higher routine discharges (53.8 vs. 51.3 %, p<0.001) and lower total charges ($47155 vs. 51909, p<0.001) than non-TUD. Although PH patients with TUD had a higher comorbidity burden, they had lower in-hospital mortality rates along with lower total charges of hospitalization, mandating real-world data to validate these results.
- 28 November 2023
- Published by Forschungsgesellschaft für Arbeitsphysiologie und Arbeitsschutz e.V. in EXCLI Journal
- Vol. 22, 1200-1210
Open AccessPrevalence and impact of tobacco use disorder on in-hospital mortality in patients hospitalized with non-group 1 pulmonary hypertension
Numerous studies indicated that patients with tobacco use disorder (TUD) are inversely associated with mortality in what is known as the smoker's paradox. However, limited studies have been conducted on the impact of TUD on the in-hospital mortality rates of patients with secondary pulmonary hypertension (PH, Non-Group 1 PH). Using the 2019 National Inpatient Sample, we identified PH and divided it into TUD and non-TUD to compare the comorbidities and in-hospital mortality between the two after 1:1 propensity-score matching. Of 1,129,440 PH hospitalizations, 12.1 % had TUD. After matching (n=133545, each group), TUD had lower median age (62 vs. 63), higher females (49 vs. 46.6 %), blacks (25.9 vs. 25.3 %), lower household income (40.8 vs. 32.7 %), Medicaid (22.4 vs. 14.8 %), non-elective (93.5 vs. 89.8 %), rural (9.3 vs. 6.7 %), urban non-teaching (17.2 vs 15.8 %) admissions. All CV comorbidities and other substance use were higher in TUD except CHF and valvular heart disease, TUD+ cohort and lower mortality (3.3 vs. 4.2 %, OR 0.78, p<0.001), higher routine discharges (53.8 vs. 51.3 %, p<0.001) and lower total charges ($47155 vs. 51909, p<0.001) than non-TUD. Although PH patients with TUD had a higher comorbidity burden, they had lower in-hospital mortality rates along with lower total charges of hospitalization, mandating real-world data to validate these results.